Nisshin Flour Milling Co., Ltd.

Nisshin Seifun Group Inc.

Norio Oshida

Makoto Yanai

Masashi Suzuki

Shigeru Hiramoto

Nobuhiro Kinoshita

Koji Kawamura

Akiko Shingai

Orie Yasuda

Masako Takasu

Toshihiro Takahashi

Kohei Inomata

Tamiko Hamada

Hiroaki Satoh

Noriyoshi Sueda

Toshiji Sugai

Hitoshi Inoue

Einosuke Sakurai

Masato Horigome

Hiroyuki Yamazaki

Shinji Yokoyama

Hiroshi Sakai

Koichi Itoh

Katsutoshi Miura

Kazuhiko Yamada

Takao Kishiye

Yoko Tsukada

Fumihisa Nakata

Yukiko Muraki

Kazumi Nishimura

Yoji Mimaki

Tomomi Tonoike

Tsutomu Takasawa

Kouji Kawamura

Hiroyuki Ikemoto

Koichi Katsuyama

Koichi Katasuyama

Nobutoshi Kubota

Naohito Iwata

Cyclic depsipeptides represented by the formulawherein: R is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15-carbon atoms; A, B, D, E and F independently each other are alanine, valine, leucine, isoleucine, phenylalanine, etc.; W and Z independently each other are aspartic acid, asparagine, glutamic acid or glutamine; and m and n independently each other is 0 or 1, or pharmacologically acceptable salts thereof. The present compounds are prepared according to a method conventionally used in peptide synthesis. The present compounds are useful as an agent for promoting the production of apolipoprotein E, a therapeutic agent for neurologic damages, a therapeutic agent for dementia, an agent for inhibiting the production of apolipoprotein B, an agent for promoting the production of apolipoprotein A1 or a therapeutic agent for hyperlipemia.

Cyclic depsipeptides and drugs containing the same as the active ingredient

A depsipeptide containing N-substituted glycine residue having the formula (1) or (2):

Depsipeptides containing N-substituted glycine residue

The present invention provides a new depsipeptide derivative having a piperazinone ring within the molecule which is represented by formula (1)

Depsipeptide derivatives bearing piperazinone rings

Depsipeptides represented by the formula (1):

Depsipeptides and drugs containing the same as the active ingredient

A depsipeptide containing a non-natural amino acid(s) having the formula (1)

Depsipeptides containing non-natural amino acids

The present invention provides a bicyclic depsipeptide having the formula (1)

Bicyclic depsipeptides

1,4-benzodioxin derivatives

Pyridinecarboxamide derivatives

There is disclosed a multidrug resistance inhibitor for overcoming a multidrug resistance of cancer, or an agent for enhancing the activity of anti-cancer agents, which comprises as an active ingredient a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein n is an integer of 5 to 12,

Multidrug resistance inhibitors

A depsipeptide containing N-substituted glycine residue having the formula (1) or (2): ##STR1## (wherein R.sub.1 is a straight or branched alkyl group of 5-20 carbon atoms or a straight or branched alkoxymethyl group of 5-15 carbon atoms; R.sub.2 is a group of the formula --A--B--W--(D).sub.m --(E).sub.n, --A--B--W--(D).sub.m --(E).sub.n --F or --A--B--W--(D).sub.m --(E).sub.n --F--Z; R.sub.3 is a hydroxyl group, a lower alkoxy group, a benzyloxy group, or a group of the formula --Z, --Z--G or --Z--G--J; A, B, D, E, F, G and J independently are an N-substituted glycine residue or a residue of an amino acid selected from the group consisting of alanine, valine, leucine, serine, etc.; W and Z independently are a residue of an amino acid selected from the group consisting of an aspartic acid, a glutamic acid, etc.; at least one of A, B, D, E, F, G and J is an N-substituted glycine residue) or a pharmacologically acceptable salt thereof. The above depsipeptides have a promoting activity on the production of apolipoprotein E, and are useful as a therapeutic agent for neurologic damages, especially dementia, and hyperlipemia.

Isoprene derivatives of formula (I) ##STR1## wherein m is an integer of 0 to 3,

Isoprene derivatives

Urea derivatives of formula (I) ##STR1## wherein the valuable groups are as defined in the specification, which possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

Urea derivatives and their use as ACAT inhibitors

Urea derivatives of formula (1) ##STR1## wherein the valuable groups are as defined in the specification, which possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

Growing community of inventors

Saitama-ken, Japan

Norio Oshida